The study by Zhan et al 1 evaluated the effect of nicorandil on contrast-induced nephropathy (CIN). They reported that nicorandil significantly prevented CIN in patients who underwent a coronary angiogram and/or percutaneous coronary intervention. We have the following comments. Figures 3 and 4 are forest plots, not funnel plots. We demonstrated these 2 figures with software (Review Manager 5.3) and got the same plots. Table 1 described gender and age in detail. However, the authors did not take into account differences in gender and age in different articles, which may lead to significant heterogeneity.
Differences in administration can affect the results. Among the 5 cited articles, in 3 (Guo, 2 Fan, 3 and Iranirad 4 ), nicorandil was administrated orally, while in the other 2 (Ko 5 and Nawa 6 ), nicorandil was administrated intravenously. Using software (Stata 12.0), we found that there is a significant difference between the results of oral and intravenous administration. This problem cannot be ignored.
The 5 articles cited by the authors all come from the Asian region and do not take ethnic differences into account. We do not know whether the authors' conclusion (ie, nicorandil can prevent CIN) is true elsewhere.
Multivariate and univariate factors can affect the results. There were differences in the types of analyses of the relevant studies. As a result, a subgroup analysis should be down to investigate significant heterogeneity.
We suggest that subgroup analyses should be carried out in this article. Further studies are required to support the conclusions (ie, nicorandil can prevent CIN).
